Silo Financial Statements From 2010 to 2025
| SILO Stock | USD 1.83 0.01 0.54% |
Check Silo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Silo Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Silo financial statements analysis is a perfect complement when working with Silo Pharma Valuation or Volatility modules.
Silo |
Silo Pharma OTC Stock Return On Equity Analysis
Silo Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Silo Pharma Return On Equity | -0.44 |
Most of Silo Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Silo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Silo Pharma has a Return On Equity of -0.4397. This is 98.17% lower than that of the Biotechnology sector and 98.79% lower than that of the Health Care industry. The return on equity for all United States stocks is 41.84% higher than that of the company.
Silo Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Silo Pharma's current stock value. Our valuation model uses many indicators to compare Silo Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Silo Pharma competition to find correlations between indicators driving Silo Pharma's intrinsic value. More Info.Silo Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Silo Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Silo Pharma's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Silo Pharma Financial Statements
Silo Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how Silo OTC Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
Pair Trading with Silo Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silo Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Silo OTC Stock
| 0.79 | VERA | Vera Therapeutics | PairCorr |
| 0.73 | DSGN | Design Therapeutics | PairCorr |
| 0.6 | VINC | Vincerx Pharma | PairCorr |
| 0.47 | VANI | Vivani Medical | PairCorr |
| 0.4 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to Silo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silo Pharma to buy it.
The correlation of Silo Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.